Show simple item record

dc.contributor.advisorSlack, Marionen
dc.contributor.authorPatel, Rajal
dc.contributor.authorSkuba, Katrina
dc.contributor.authorWild, Michelle
dc.contributor.authorSlack, Marion
dc.date.accessioned2016-06-22T22:36:11Z
dc.date.available2016-06-22T22:36:11Z
dc.date.issued2013
dc.identifier.urihttp://hdl.handle.net/10150/614272
dc.descriptionClass of 2013 Abstracten
dc.description.abstractSpecific Aims: To determine the effectiveness of exenatide twice daily (ExBID) versus exentatide once weekly (ExQW) on weight loss in type II diabetes. Methods: This study was a meta-analysis. The studies used came from the PubMed database and Cochrane Reviews. To be included in the meta-analysis, studies must have been randomized controlled trials comparing ExBID to ExQW or drug to placebo. The studies that reported weight loss and/or HbA1C were included. Studies that included participants <18 years of age or compared only one dose of exenatide with other anti-diabetic medication without comparing to placebo were excluded. There were 13 studies that met the inclusion criteria and were included in the meta-analysis. The primary outcome was weight loss, and the secondary outcome was HbA1C levels. Meta-analysis was used to synthesize data. Main Results: The difference between ExQW and ExBID on weight loss was not statistically significant (standardized mean difference (SMD) = -0.71, CI -0.84 to -0.58 in ExQW vs SMD = 0.82, CI -1.02 to -0.62 in ExBID; p =0.36). The effect of ExQW on A1C was significantly larger than ExBID (SMD = -1.69 vs -1.07 respectively; p < 0.01). The variability was very high in the ExBID group (69% - 81%) compared to ExQW group (0%). Kendall’s tau was significant (p= 0.01) indicating that there may be publication bias. Conclusion: There is no difference in effect of weight loss between ExQW and ExBID group. Both dosages significantly improve A1C; however, ExBID has larger impact on A1C compared to ExBID.
dc.language.isoen_USen
dc.publisherThe University of Arizona.en
dc.rightsCopyright © is held by the author.en
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/
dc.subjectdiabetesen
dc.subjectWeight Lossen
dc.subjectexenatide twice daily (ExBID)en
dc.subjectexentatide once weekly (ExQW)en
dc.subject.meshWeight Loss
dc.subject.meshDiabetes Mellitus, Type 2
dc.titleEffects of Exenatide Twice Daily and Once Weekly on Weight Lossen_US
dc.typetexten
dc.typeElectronic Reporten
dc.contributor.departmentCollege of Pharmacy, The University of Arizonaen
dc.description.collectioninformationThis item is part of the Pharmacy Student Research Projects collection, made available by the College of Pharmacy and the University Libraries at the University of Arizona. For more information about items in this collection, please contact Jennifer Martin, Librarian and Clinical Instructor, Pharmacy Practice and Science, jenmartin@email.arizona.edu.en
html.description.abstractSpecific Aims: To determine the effectiveness of exenatide twice daily (ExBID) versus exentatide once weekly (ExQW) on weight loss in type II diabetes. Methods: This study was a meta-analysis. The studies used came from the PubMed database and Cochrane Reviews. To be included in the meta-analysis, studies must have been randomized controlled trials comparing ExBID to ExQW or drug to placebo. The studies that reported weight loss and/or HbA1C were included. Studies that included participants <18 years of age or compared only one dose of exenatide with other anti-diabetic medication without comparing to placebo were excluded. There were 13 studies that met the inclusion criteria and were included in the meta-analysis. The primary outcome was weight loss, and the secondary outcome was HbA1C levels. Meta-analysis was used to synthesize data. Main Results: The difference between ExQW and ExBID on weight loss was not statistically significant (standardized mean difference (SMD) = -0.71, CI -0.84 to -0.58 in ExQW vs SMD = 0.82, CI -1.02 to -0.62 in ExBID; p =0.36). The effect of ExQW on A1C was significantly larger than ExBID (SMD = -1.69 vs -1.07 respectively; p < 0.01). The variability was very high in the ExBID group (69% - 81%) compared to ExQW group (0%). Kendall’s tau was significant (p= 0.01) indicating that there may be publication bias. Conclusion: There is no difference in effect of weight loss between ExQW and ExBID group. Both dosages significantly improve A1C; however, ExBID has larger impact on A1C compared to ExBID.


This item appears in the following Collection(s)

Show simple item record